Global Platinum-Based Anti-Cancer Drugs Market Driven by Increasing Adoption of Advanced Chemotherapy Treatments
Global platinum-based anti-cancer drugs market is driven by the rising incidence of cancer worldwide, increasing demand for effective chemotherapy drugs, and continuous advancements in oncology treatment solutions. The growing utilization of platinum-based drugs including cisplatin, carboplatin, and oxaliplatin for treating lung cancer, breast cancer, testicular cancer, and several other malignancies is significantly contributing to market growth. In addition, increasing healthcare expenditure, expanding cancer research activities, and rising adoption of combination therapies and precision medicine approaches are further supporting the expansion of the platinum-based anti-cancer drugs market globally.
Browse the full report description of “Global Platinum-Based Anti-Cancer Drugs Market Size, Share & Trends Analysis Report, By Product Type (Cisplatin, Carboplatin, Oxaliplatin, and Others), By Application (Testicular Cancer, Lung Cancer, Breast Cancer, and Others), Forecast (2021-2027)” at https://www.omrglobal.com/industry-reports/platinum-based-anti-cancer-drugs-market
Advancements in platinum-resistant ovarian cancer therapies are expected to drive oncology treatment innovation in 2026
The oncology market is expected to witness significant advancements in platinum-resistant cancer treatment in 2026 due to increasing research activities focused on improving survival outcomes for patients with limited therapeutic options. Rising prevalence of recurrent ovarian cancer and growing resistance to platinum-based chemotherapy are encouraging pharmaceutical companies to develop advanced immunotherapy-based treatment combinations. In February 2026, Merck & Co. announced positive Phase 3 KEYNOTE-B96 trial results showing that KEYTRUDA® (pembrolizumab) combined with paclitaxel, with or without bevacizumab, significantly improved overall survival in patients with platinum-resistant recurrent ovarian cancer. The development represents a major advancement in oncology treatment strategies and highlights the growing adoption of combination immunotherapies for difficult-to-treat cancers. Additionally, increasing investments in precision oncology, biomarker-driven therapies, and next-generation cancer immunotherapies are expected to further strengthen innovation across the platinum-resistant cancer treatment market.
Development of platinum-free cancer therapies is expected to expand treatment alternatives in 2025
The oncology market is expected to experience growing demand for platinum-free treatment approaches in 2025 as pharmaceutical companies focus on reducing toxicity concerns and improving treatment accessibility for patients who are ineligible for platinum-based chemotherapy. Increasing emphasis on targeted therapies and immunotherapy combinations is driving the development of new standards of care for bladder cancer and other solid tumors. In December 2025, Pfizer and Astellas Pharma announced positive Phase 3 results showing that PADCEV™ plus Keytruda® significantly improved survival rates in muscle-invasive bladder cancer patients regardless of cisplatin eligibility. The companies highlighted the therapy’s potential to become a new platinum-free standard of care for bladder cancer treatment. Furthermore, rising clinical adoption of immuno-oncology therapies and increasing focus on personalized cancer treatment approaches are expected to accelerate growth within the platinum-free oncology therapeutics segment.
Regulatory support for next-generation platinum-resistant cancer therapies is expected to accelerate oncology drug development in 2025
The oncology therapeutics market is expected to benefit from increasing regulatory support and accelerated approval pathways for innovative cancer treatments targeting platinum-resistant diseases. Pharmaceutical companies are focusing on developing next-generation antibody-drug conjugates and targeted oncology therapies to address unmet medical needs in recurrent and treatment-resistant cancers. In August 2025, Genmab received FDA Breakthrough Therapy Designation for Rina-S® (rinatabart sesutecan) for recurrent or progressive endometrial cancer patients whose disease progressed after platinum-containing regimens and PD-(L)1 therapy. The designation is expected to accelerate clinical development and regulatory review processes for advanced therapies targeting platinum-resistant cancers. Additionally, increasing collaboration between regulatory agencies and biopharmaceutical companies is anticipated to support faster commercialization of innovative oncology therapies across the global cancer treatment market.
About OMR Global
OMR Global is a market intelligence and strategic consulting firm specializing in growth advisory, competitive intelligence, and AI-enabled business research across global B2B industries.
The company supports enterprises, investors, and technology providers with actionable insights for market entry, investment analysis, procurement strategy, commercialization, and business expansion. OMR Global combines industry expertise, primary research, analytics, and digital intelligence tools to help organizations navigate evolving market landscapes and identify growth opportunities.
OMR Digital Offerings
- Pulse Intelligence Platform – AI-powered market intelligence suite designed to deliver analyst-grade insights faster and more efficiently. Built on 12+ years of research expertise and enhanced with AI-driven analytics, Pulse helps organizations transform large volumes of market and company data into actionable intelligence within hours instead of weeks. Trusted by Fortune 500 enterprises, global investment banks, strategy consultancies, and PE & VC firms, Pulse supports strategic decision-making across investment evaluation, competitive benchmarking, AI readiness, and market positioning.
Other Offerings
- Lead Generation – Verified B2B prospect data, ICP targeting, and intent-based sales intelligence
- RFx Support – End-to-end RFP, RFI, and RFQ support with vendor benchmarking and evaluation frameworks
OMR Global delivers data-driven intelligence solutions designed to support strategic decision-making, operational efficiency, and long-term business growth.
To find out more, visit www.omrglobal.com
Contact:
Mr. Anurag Tiwari
305-308, Commerce House, Janjeerwala Square,
Indore, Madhya Pradesh 452001
India
+91-780-304-0404